Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study.

about

Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study.

Item

http://www.wikidata.org/entity/Q50083411

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Trastuzumab-modified DM1-loade ...... an in vitro and in vivo study.

@en

Trastuzumab-modified DM1-loade ...... an in vitro and in vivo study.

@nl

type

Item

label

Trastuzumab-modified DM1-loade ...... an in vitro and in vivo study.

@en

Trastuzumab-modified DM1-loade ...... an in vitro and in vivo study.

@nl

prefLabel

Trastuzumab-modified DM1-loade ...... an in vitro and in vivo study.

@en

Trastuzumab-modified DM1-loade ...... an in vitro and in vivo study.

@nl

P1476

Trastuzumab-modified DM1-loade ...... an in vitro and in vivo study.

@en

P2093

Amin Li

http://www.w3.org/2001/XMLSchema#string

Ling Rong

http://www.w3.org/2001/XMLSchema#string

Shiyu Cai

http://www.w3.org/2001/XMLSchema#string

Shuping Zhou

http://www.w3.org/2001/XMLSchema#string

Tao Jing

http://www.w3.org/2001/XMLSchema#string

Xiaolong Tang

http://www.w3.org/2001/XMLSchema#string

Xinkuang Liu

http://www.w3.org/2001/XMLSchema#string

Xueke Liu

http://www.w3.org/2001/XMLSchema#string

Yinci Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges

Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).

Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.

Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer

Immuno nanoparticles integrated electrical control of targeted cancer cell development using whole cell bioelectronic device.

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.

Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.

Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.

P304

1-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21691401.2017.1391821

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29069935

http://www.w3.org/2001/XMLSchema#string